Abstract
The endothelium plays a crucial role in the pathogenesis of cardiovascular disease. Endothelial function is attenuated by the presence of different well known cardiovascular risk factors. Evaluation of endothelial vasodilator function serve as an index integrating the overall stress imposed by cardiovascular risk factors and reinforce the suggestion that endothelial dysfunction is an early marker of cardiovascular disease that precedes clinical manifestations. Angiotensin-converting enzyme inhibitors have been shown to reduce the cardiovascular mortality, an effect that could be the consequence of an improvement in the endothelial function. Recent studies have shown that a calcium antagonist might improve the endothelial function, however, there is controversy about this action and also about the potential mechanisms for the effect of a calcium antagonist in the regulation of endothelial function.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Moncada S et al. The L-arginine: nitric oxide pathway J Cardiovasc Pharmacol 1991 17: S1–S9
López-Jaramillo P, Guarner F, Moncada S . Effects of calcium and parathyroid hormone on prostacyclin synthesis by vascular tissue Life Sci 1987 40: 983–986
López-Jaramillo P, González MC, Palmer RMJ, Moncada S . The crucial role of physiological Ca2+ concentrations in the production of endothelial nitric oxide and the control of vascular tone Br J Pharmacol 1990 101: 489–493
Lusher T . The endothelium and cardiovascular disease a complex relation N Engl J Med 1994 330: 1001–1003
Celermajer DS et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis Lancet 1992 340: 1111–1115
Dakak N et al. Contribution of nitric oxide to reactive hyperemia. Impact of endothelial dysfunction Hypertension 1998 32: 9–15
Hijmering ML et al. Non-invasive evaluation of vascular function Eur Heart J 1999 1 (Suppl): M16–M18
Accini JL et al. Colombian study to Assess the use of Noninvasive Determination of Endothelium-mediated Vasodilation (CANDEV). Normal values and factors associated Endothelium 2000 8: 157–166
Schroeder S et al. Noninvasive determination of endothelium-mediated vasodilation as a screening test for coronary artery disease: pilot study to assess the predictive value in comparision with angina pectoris, exercise electrocardiography, and myocardial perfusion imaging Am Heart J 1999 138: 731–739
Schachinger V, Britten MB, Zeiher AM . Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease Circulation 2000 101: 1899–1906
Takase B et al. Endothelium-dependent flow-mediated vasodilation in coronary and brachial arteries in suspected coronary artery disease Am J Cardiol 1998 82: 1535–1539
Anderson TJ et al. Close relation of endothelial function in the human coronary and peripheral circulation J Am Coll Cardiol 1995 26: 1235–1241
Suwaidi JA et al. Long-term follow-up ofpatients with mild coronary artery disease and endothelial dysfunction Circulation 2000 101: 948–954
Neunteufl T et al. Late prognostic value of flow-mediated dilation in the brachial artery ofpatients with chest pain Am J Cardiol 2000 86: 207–210
Shepherd JH et al. For the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia N Engl J Med 1995 333: 1301–1307
Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S) Lancet 1994 344: 1383–1389
Luscher T . Endothelial dysfunction: the role and impact of the renin-angiotensin system Heart 2000 84 (Suppl I): i20–i22
Pfeffer MA . ACE inhibition in acute myocardial infarction N Engl J Med 1995 332: 118–120
The Heart Outcomes Prevention Evaluation Study (HOPE) investigators. Effects of an Angiotensin Converting enzyme inhibitor, Ramipril, on cardiovascular events in high riskpatients N Engl J Med 2000 342: 145–153
SOLVD investigators. Effect of Enalapril on mortality and the development of heart failure in asymptomaticpatients with reduced left ventricular ejection fraction N Engl J Med 1992 327: 685–691
Vanhoutte P . Endothelium-dependent effects of converting-enzyme inhibitors J Cardiovasc Pharmacol 1993 22: S10–S16
Mancini J et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction inpatients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) Study Circulation 1996 94: 258–265
Anderson TJ et al. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation inpatients with coronary disease (BANFF Study) J Am Coll Cardiol 2000 35: 60–66
Sudhir K et al. Effects of selective angiotensin II receptor antagonism and angiotensin converting enzyme inhibition on the coronary vasculature in vivo: intravascular two-dimensional and doppler ultrasound studies Circulation 1993 87: 931–938
Griendling KK, Mineri CA, Ollerenshaw JD, Alexander RW . Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells Circ Res 1994 74: 1141–1148
Frielingsdorf J et al. Normalization of abnormal coronary vasomotion by calcium antagonists inpatients with hypertension Circulation 1996 93: 1380–1387
Kaufmman P et al. Reversal of abnormal coronary vasomotion by calcium antagonist inpatients with hypercholesterolemia Circulation 1998 97: 1348–1354
Zhang X, Hintze TH . Amlodipin releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent Circulation 1998 97: 576–580
Kitakaze M et al. Nifedipine-induced coronaryvasodilation in ischemic hearts is attributable to bradykinin-and NO-dependent mechanism in dogs Circulation 2000 101: 311–317
Ding Y, Vaziri D . Nifedipine and diltiazem but not verapamil up-regulate endothelial nitric-oxide synthase expression J Pharmacol Exp Ther 2000 292: 606–609
Lansman JB, Hallam TJ, Rink TJ . Single stretch-activated ion channels in vascular endothelial cells as mechanotransducers Nature 1987 325: 811–813
Chen L et al. Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects ofvitamin E, lovastatin and amlodipine J Am Coll Cardiol 1997 30: 569–575
Horning B, Kohler C, Drexler H . Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans Circulation 1997 95: 1115–1118
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
López-Jaramillo, P., Casas, J. Endothelial dysfunction, angiotensin-converting enzyme inhibitors and calcium antagonists. J Hum Hypertens 16 (Suppl 1), S34–S37 (2002). https://doi.org/10.1038/sj.jhh.1001339
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.jhh.1001339